"Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma" by J. M. Timmerman

Selected Works of John M. Pagel, MD, PhD

Follow Contact

Article

Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma

Journal of Clinical Oncology (2008)

J. M. Timmerman, University of California, Los Angeles
J. C. Byrd, Ohio State University
D. J. Andorsky, University of California, Los Angeles
M. F. Siadak
T. A. DeVries, University of Washington
D. F. Hausman, University of Washington
J. M. Pagel, Fred Hutchinson Cancer Research Center

Link

Disciplines

Medicine and Health Sciences,
Oncology and
Pathology

Publication Date

May 20, 2008

DOI

10.1200/jco.2008.26.15_suppl.8554

Citation Information

J. M. Timmerman, J. C. Byrd, D. J. Andorsky, M. F. Siadak, et al.. "Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma" Journal of Clinical Oncology Vol. 26 (2008) p. 8554 - 8554
Available at: http://works.bepress.com/john-pagel/224/